Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. raised Karyopharm Therapeutics from a neutral rating to an overweight rating and upped their target price for the company from $8.00 to $16.00 in a research note on Tuesday, July 23rd. HC Wainwright reaffirmed a buy rating and issued a $32.00 target price (up previously from $29.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. Zacks Investment Research lowered Karyopharm Therapeutics from a buy rating to a hold rating in a research note on Saturday, July 13th. Robert W. Baird reaffirmed an outperform rating and issued a $25.00 target price (up previously from $15.00) on shares of Karyopharm Therapeutics in a research note on Friday, July 5th. Finally, BidaskClub raised Karyopharm Therapeutics from a hold rating to a buy rating in a research note on Saturday, August 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $17.32.
KPTI stock opened at $8.60 on Monday. Karyopharm Therapeutics has a 1 year low of $3.92 and a 1 year high of $21.71. The company has a current ratio of 6.93, a quick ratio of 6.93 and a debt-to-equity ratio of 1.46. The company has a 50 day moving average of $8.13. The stock has a market cap of $540.57 million, a price-to-earnings ratio of -2.74 and a beta of 2.40.
Several institutional investors have recently modified their holdings of KPTI. Point72 Asset Management L.P. purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter worth $15,552,000. Frontier Capital Management Co. LLC lifted its stake in shares of Karyopharm Therapeutics by 311.9% during the 1st quarter. Frontier Capital Management Co. LLC now owns 683,363 shares of the company’s stock worth $3,991,000 after purchasing an additional 517,464 shares during the period. First Midwest Bank Trust Division lifted its stake in shares of Karyopharm Therapeutics by 259.2% during the 1st quarter. First Midwest Bank Trust Division now owns 610,850 shares of the company’s stock worth $3,567,000 after purchasing an additional 440,769 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Karyopharm Therapeutics by 158.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 673,774 shares of the company’s stock worth $6,313,000 after purchasing an additional 413,409 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Karyopharm Therapeutics by 14.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,983,862 shares of the company’s stock worth $17,874,000 after purchasing an additional 369,590 shares during the period. 83.91% of the stock is currently owned by institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Featured Story: How Does the Quiet Period Work?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.